GlassScriptPhysician profile
Manthodi K Faisal
NPI 1245396787
$5,518.35
in general payments reported to CMS, 2019-2025
34 companies · $819 in 2025
The $819 reported for 2025 was more than what a typical Nephrology (Internal Medicine) provider received nationally (typical 2025 total: $311).
See the full distribution for Nephrology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $904 · 2020: $238 · 2021: $551 · 2022: $719 · 2023: $1,046 · 2024: $1,242 · 2025: $819.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,967 · Education: $141.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,966.72 |
| Education | $140.59 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $625.51 | 2019-2025 | Farxiga, Lokelma |
| Mallinckrodt Hospital Products INC. | $616.01 | 2021-2025 | Acthar |
| Vifor Pharma, INC. | $552.49 | 2019-2025 | Veltassa, Korsuva |
| Fresenius USA Marketing, INC. | $515.57 | 2019-2025 | Velphoro, Velphoro |
| Amgen INC. | $487.14 | 2019-2025 | Tavneos, Krystexxa, Parsabiv |
| Horizon Therapeutics Plc | $414.24 | 2019-2023 | Krystexxa |
| Travere Therapeutics, INC. | $347.71 | 2019-2025 | |
| Otsuka America Pharmaceutical, INC. | $304.78 | 2019-2025 | Jynarque |
| Bayer Healthcare Pharmaceuticals INC. | $213.02 | 2021-2024 | |
| Ardelyx, INC. | $163.67 | 2024-2025 | Ibsrela |
| Daiichi Sankyo INC. | $149.87 | 2019-2024 | Injectafer |
| Calliditas Therapeutics US INC. | $114.74 | 2022-2025 | Tarpeyo |
| Opko Pharmaceuticals, LLC | $105.40 | 2019-2023 | Rayaldee |
| Boehringer Ingelheim Pharmaceuticals, INC. | $96.43 | 2023-2024 | Jardiance |
| Aurinia Pharma U.S., INC. | $93.49 | 2022-2024 | Lupkynis |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Akebia Therapeutics INC | $81.80 | 2019-2025 | Vafseo, Auryxia |
| Novartis Pharmaceuticals Corporation | $79.79 | 2025 | |
| Mallinckrodt Enterprises LLC | $68.49 | 2019 | |
| Glaxosmithkline, LLC. | $61.79 | 2021-2024 | Benlysta, Jesduvroq |
| Ani Pharmaceuticals, INC. | $59.29 | 2025 | Purified Cortrophin Gel |
| Shield Therapeutics INC | $54.50 | 2024 | |
| Takeda Pharmaceuticals U.S.A., INC. | $42.97 | 2022-2023 | |
| Amag Pharmaceuticals, INC. | $38.44 | 2019-2020 | |
| Kyowa Kirin, INC. | $28.84 | 2024 | Crysvita |
| Janssen Pharmaceuticals, INC | $28.33 | 2019 | |
| Genzyme Corporation | $27.78 | 2021-2025 | |
| Genentech USA, INC. | $22.44 | 2019 | |
| Astellas Pharma US INC | $21.31 | 2023 | Cresemba |
| Shire North American Group INC | $20.47 | 2019 | |
| Inari Medical, INC. | $20.26 | 2024 | Flowtriever Catheter, S, Ct Thrombectomy System Kit |
| Alexion Pharmaceuticals, INC. | $19.93 | 2019 | |
| Ultragenyx Pharmaceutical INC. | $14.73 | 2023 | Crysvita |
| Vbi Vaccine (Delaware) INC. | $14.67 | 2022 | |
| Karyopharm Therapeutics INC. | $12.45 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Manthodi Faisal listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.